Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk
Uric acid is the final product of purine metabolism, and its increased serum levels have been
directly involved in the pathogenesis and natural history of hypertension. The relationship …
directly involved in the pathogenesis and natural history of hypertension. The relationship …
[HTML][HTML] Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions
M Freilich, A Arredondo, SL Zonnoor, IM McFarlane - Cureus, 2022 - ncbi.nlm.nih.gov
Several landmark studies found a relationship between elevated serum uric acid (SUA)
levels and cardiovascular disease (CVD). In fact, the association between hyperuricemia …
levels and cardiovascular disease (CVD). In fact, the association between hyperuricemia …
Pathophysiological mechanisms of hypertension development induced by fructose consumption
During the past several decades, there has been a dramatic increase in fructose
consumption worldwide in parallel with epidemics of metabolic diseases. Accumulating …
consumption worldwide in parallel with epidemics of metabolic diseases. Accumulating …
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk …
G Desideri, M Rajzer, M Gerritsen… - European Heart …, 2022 - academic.oup.com
Aims Hyperuricaemia and gout are strongly related with traditional cardiovascular risk
factors and vascular damage. This study aimed to assess whether febuxostat and allopurinol …
factors and vascular damage. This study aimed to assess whether febuxostat and allopurinol …
Febuxostat ameliorates high salt intake-induced hypertension and renal damage in Dahl salt-sensitive rats
T Miura, A Sakuyama, L Xu, J Qiu… - Journal of …, 2022 - journals.lww.com
Objective: Several clinical studies have reported that xanthine oxidoreductase inhibitors
have antihypertensive and renal protective effects but their mechanisms have not been fully …
have antihypertensive and renal protective effects but their mechanisms have not been fully …
[HTML][HTML] Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022
IE Chazova, YV Zhernakova, OA Kislyak… - Systemic …, 2022 - syst-hypertension.ru
After 3 years since the release of the first consensus on the management of patients with
hyperuricemia and high cardiovascular risk. During this time, new data appeared that …
hyperuricemia and high cardiovascular risk. During this time, new data appeared that …
[HTML][HTML] Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022
ИЕ Чазова, ЮВ Жернакова, ОА Кисляк… - Системные …, 2022 - cyberleninka.ru
Со времени выхода первого консенсуса по ведению пациентов с гиперурикемией и
высоким сердечно-сосудистым риском прошло 3 года. За это время появились новые …
высоким сердечно-сосудистым риском прошло 3 года. За это время появились новые …
Cardiological and rheumatological expert statement on the management of asymptomatic hyperuricemia in patients at high cardiovascular risk
M Barylski, B Batko, KJ Filipiak… - Rheumatology …, 2022 - journals.viamedica.pl
Cardiological and rheumatological expert statement on the management of asymptomatic
hyperuricemia in patients at high cardiov Page 1 43 www.journals.viamedica.pl Marcin Barylski1 …
hyperuricemia in patients at high cardiov Page 1 43 www.journals.viamedica.pl Marcin Barylski1 …
[PDF][PDF] Kardiologiczno-reumatologiczne stanowisko ekspertów dotyczące leczenia bezobjawowej hiperurykemii u pacjentów obciążonych wysokim ryzykiem sercowo …
M Barylski, B Batko, KJ Filipiak, A Mamcarz… - Varia …, 2022 - journals.viamedica.pl
Kwas moczowy (UA, uric acid) to końcowy produkt metabolizmu puryn (endogennych i
egzogennych). W przypadku większości zwierząt UA jest dalej rozkładany do alantoiny …
egzogennych). W przypadku większości zwierząt UA jest dalej rozkładany do alantoiny …